Trials / Completed
CompletedNCT07429045
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AMG 133 in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this trial is to evaluate the pharmacokinetics of a single subcutaneous (SC) dose of AMG 133 in participants with various degrees of renal impairment compared to participants with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 133 | Participants will receive one dose of AMG 133 as a SC injection. |
Timeline
- Start date
- 2025-03-11
- Primary completion
- 2025-11-21
- Completion
- 2025-11-21
- First posted
- 2026-02-24
- Last updated
- 2026-02-24
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07429045. Inclusion in this directory is not an endorsement.